Sleep Medicine Gets a Major Upgrade: Here's What Changed in 2025

Sleep medicine experienced its most transformative year yet in 2025, with groundbreaking FDA approvals, novel therapies, and updated treatment guidelines reshaping how doctors approach sleep disorders. The field saw major advances in treating obstructive sleep apnea (OSA), narcolepsy, and restless legs syndrome, offering patients more options than ever before.

What New Sleep Technologies Got FDA Approval?

The Food and Drug Administration cleared an impressive array of sleep-related devices throughout 2025, marking a shift toward more flexible care models. The most notable approval was Nyxoah's Genio hypoglossal nerve stimulation system for adults with moderate to severe obstructive sleep apnea and an apnea-hypopnea index (AHI) of 15-65. This leadless, bilateral stimulation system showed remarkable results in clinical trials, with 82% of participants achieving an AHI below 15.

The FDA also approved several home sleep testing technologies and wearables, including:

• Compumedics' Falcon HST and SomfitD: Advanced home sleep testing devices that allow patients to be diagnosed outside traditional sleep labs
• DormoTech's DormoVision X: Remote monitoring technology that provides detailed sleep analysis
• Happy Health's Happy Ring and PranaQ's TipTraQ: Wearable devices that track sleep patterns and quality metrics
• SleepRes' Kricket Positive Airway Pressure device: A new CPAP alternative that synchronizes therapy with natural breathing patterns

These approvals reflected an ongoing shift toward remote data collection and expanded access to testing while maintaining clinical standards.

How Are New Oral Medications Changing Sleep Apnea Treatment?

Perhaps the most exciting development was the advancement of oral treatments for obstructive sleep apnea. Following the FDA's late-2024 approval of Zepbound (tirzepatide) as the first prescription medication for adults with moderate-to-severe OSA and obesity, clinicians spent 2025 learning how GLP-1 therapies fit into treatment plans. About one in eight adults (12%) are currently taking a GLP-1 drug, creating new questions about patient selection and monitoring.

Two promising oral combinations advanced through clinical trials. Apnimed's AD109, which combines aroxybutynin and atomoxetine, showed impressive results in the Phase 3 SynAIRgy trial with 639 participants. The combination reduced AHI scores by 55.6% compared to placebo over 26 weeks and improved oxygen desaturation and hypoxic burden in adults with OSA who couldn't tolerate positive airway pressure therapy.

Incannex's IHL-42X, combining dronabinol and acetazolamide, received FDA Fast Track designation in December, accelerating its path to potential approval.

What Changed in Restless Legs Syndrome Treatment Guidelines?

The American Academy of Sleep Medicine made a significant shift in restless legs syndrome (RLS) treatment recommendations, advising against dopamine agonists due to augmentation risks. "The guidelines now favor iron therapies—oral or intravenous—and alpha-2-delta ligands such as gabapentin, gabapentin enacarbil, and pregabalin," explained John W. Winkelman, MD, PhD, at SLEEP 2025.

This represents a major change in how doctors approach RLS treatment, emphasizing safer long-term management strategies. The new approach involves addressing aggravating factors like certain antidepressants, sleep apnea, and alcohol before slowly tapering dopamine agonists over 6-12 months.

The field also celebrated major milestones in 2025. The American Academy of Sleep Medicine marked its 50th anniversary, while the SLEEP annual meeting in Seattle recorded the highest attendance in the conference's 40-year history, with more than 6,000 participants. Match Day also filled a record 208 sleep medicine fellowship positions for the 2026 appointment year, indicating growing interest in the specialty.

These advances collectively represent a shift toward more personalized, accessible sleep medicine that extends beyond traditional sleep laboratories while maintaining rigorous clinical standards. For patients struggling with sleep disorders, 2025's innovations offer new hope for better rest and improved quality of life.